• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH initiative—called UNIT...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Monoclonal Antibodies Specific for the E2 Glycoprotein of Hepatitis C Virus and Their Use in the Diagnosis, Treatment and Prevention of Hepatitis C
Hepatitis C virus is an enveloped, single stranded RNA virus, approximately 50 nm in diameter, that has been classified as a separate genus in the Flaviviridae family. Most persons infected with hepatitis C virus develop chronic infection. These chronically infected individuals have a relatively high risk of developing chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. There is currently no vaccine to prevent the hepatitis C virus infection. The present invention relates to human monoclonal antibodies which exhibit immunological binding affinity for the hepatitis C virus E2 glycoprotein and are cross-reactive...
Source: NIH OTT Licensing Opportunities - July 6, 2020 Category: Research Authors: ott-admin Source Type: research

Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study: a discrete choice experiment.
CONCLUSIONS: Severe SE, not outcomes, was the most decisive attribute determining future HCRCT participation. Particular attention should be paid to providing clear information, in particular on severe SE, to potential participants. Immunotherapy would appear to be the best HCRCT candidate for both PLWH and physicians. However, if the risk of cancer could be avoided, gene therapy would become the preferred strategy for the latter and the second choice for the former. PMID: 32077248 [PubMed - in process]
Source: Journal of the International AIDS Society - February 22, 2020 Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research

Hepatic Natural Killer Cells: Organ-Specific Sentinels of Liver Immune Homeostasis and Physiopathology
Joanna Mikulak1,2, Elena Bruni1,2, Ferdinando Oriolo1,2, Clara Di Vito1 and Domenico Mavilio1,2* 1Unit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Milan, Italy 2Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy The liver is considered a preferential tissue for NK cells residency. In humans, almost 50% of all intrahepatic lymphocytes are NK cells that are strongly imprinted in a liver-specific manner and show a broad spectrum of cellular heterogeneity. Hepatic NK (he-NK) cells play key roles in tuning liver immune response in b...
Source: Frontiers in Immunology - April 29, 2019 Category: Allergy & Immunology Source Type: research

Leukocyte Heparanase: A Double-Edged Sword in Tumor Progression
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - April 29, 2019 Category: Cancer & Oncology Source Type: research

Trump Wants to End HIV Within 10 Years. Here ’s What That Would Take, According to Experts
About 1.1 million Americans currently live with HIV, and approximately 40,000 are infected each year, according to federal data. But in his State of the Union address, President Donald Trump promised to “eliminate the HIV epidemic in the United States within 10 years” — a plan that hinges on a multi-agency push for better diagnosis, treatment and prevention in at-risk communities, health officials said Wednesday. Trump introduced the plan during his annual address on Tuesday but offered few details. Health officials fleshed out the plan during a call with reporters on Wednesday. The initiative will be ove...
Source: TIME: Health - February 6, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime HIV/AIDS onetime Source Type: news

Gene therapy using CAR T cells could provide long-term protection against HIV
FINDINGSA UCLA-led research team has created blood-forming stem cells that can carry a gene that allows the body to produce cells that can detect and destroy HIV-infected cells. The blood-forming cells, called hematopoietic stem and progenitor cells, or HSPCs, have been engineered to carry chimeric antigen receptor, or CAR, genes that allows the production of immune cells that target cells infected with HIV.After being transplanted into the body, the engineered cells formed immune cells that not only destroyed the infected cells, but also lived for more than two years. This suggests that they have the potential to give peo...
Source: UCLA Newsroom: Health Sciences - January 25, 2018 Category: Universities & Medical Training Source Type: news